BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the first quarter ended March 31. Visit Amwell’s investor relations website at investors.amwell.com to view the first quarter 2025 earnings report.
The company will host a conference call to discuss its financial results today at 5 p.m. ET, May 1. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/9tn5fcf6. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com.
About Amwell
Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell platform includes software and services that power many clinical programs from Amwell and our growing number of partners. Our platform allows patients to experience unified, personalized and simple access to diversified clinical programs across the care continuum. As more people seek care online and more clinical programs become available, we offer integrated, future-ready, consistent solutions. The Amwell platform is proven, operating at a large scale, enabling care for millions of patients and their sponsors while delivering dependable outcomes. For almost two decades, Amwell has proudly served some of the largest and most sophisticated healthcare organizations in the U.S. and worldwide. For more information, visit business.amwell.com or LinkedIn.
Contacts
Media:
Angela Vogen
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Sue Dooley
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.45 |
Daily Change: | -0.23 -4.05 |
Daily Volume: | 106,245 |
Market Cap: | US$79.030M |
August 05, 2025 February 12, 2025 January 15, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load